Cargando…

Isoniazid-Induced Severe Hepatotoxicity: An Infrequent but Preventable Cause of Liver Failure in Children Treated for Latent Tuberculosis Infection

Isoniazid (INH) monotherapy has gained widespread acceptance as an efficacious therapy for latent tuberculosis infection (LTBI) especially in low-prevalence settings. Although INH related hepatotoxicity is well recognized, progression to severe liver dysfunction requiring care at a transplant center...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desrochers, Dan, González-Peralta, Regino P., McClenathan, Daniel T., Wilsey, Michael J., Haafiz, Allah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2011
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667043/ https://www.ncbi.nlm.nih.gov/pubmed/23761995 http://dx.doi.org/10.4137/CMPed.S6406

Ejemplares similares

1694 Risk factors and outcomes of isoniazid hepatotoxicity in children with latent tuberculosis
por: Devrim, Ilker, et al.
Publicado: (2014)

Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis
por: Oscanoa, Teodoro J., et al.
Publicado: (2023)

Isoniazid metabolism and hepatotoxicity
por: Wang, Pengcheng, et al.
Publicado: (2016)

A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis
por: Philipose, Jobin, et al.
Publicado: (2022)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
por: Sistanizad, Mohammad, et al.
Publicado: (2011)

The pacemaker-twiddler’s syndrome: an infrequent cause of pacemaker failure
por: Salahuddin, Mohammad, et al.
Publicado: (2016)

Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis
por: Torres, Martha, et al.
Publicado: (2015)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors
por: Lai, Edward Chia-Cheng, et al.
Publicado: (2021)

Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2020)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area
por: Moon, Hyung Hwan, et al.
Publicado: (2017)

BIOEFFICIENCY OF INDIGOGERA TINCTORIA LINN. ON ISONIAZID INDUCED HEPATOTOXICITY IN ALBINORATS
por: Chitra, M., et al.
Publicado: (2003)

Protective Effects of Metallothionein on Isoniazid and Rifampicin-Induced Hepatotoxicity in Mice
por: Lian, Yong, et al.
Publicado: (2013)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Elevated Alkaline Phosphatase in Children: An Algorithm to Determine When a “Wait and See” Approach is Optimal
por: Otero, Jaclyn L., et al.
Publicado: (2011)

An Infrequently Encountered Cause of Hemoptysis
por: Banjade, Prakash, et al.
Publicado: (2023)

Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co–therapy
por: Li, Feng, et al.
Publicado: (2013)

Publisher Correction: Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors
por: Lai, Edward Chia‑Cheng, et al.
Publicado: (2021)

Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study
por: Denholm, Justin T, et al.
Publicado: (2014)

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
por: Ha, Lawrence, et al.
Publicado: (2017)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report
por: Li, Tsung-Lun, et al.
Publicado: (2021)

Violent Hiccups: An Infrequent Cause of Bradyarrhythmias
por: Suh, William M., et al.
Publicado: (2009)

Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature
por: Kabbara, Wissam K., et al.
Publicado: (2016)

Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea
por: Russom, Mulugeta, et al.
Publicado: (2018)

Dexamethasone Pretreatment Alleviates Isoniazid/Lipopolysaccharide Hepatotoxicity: Inhibition of Inflammatory and Oxidative Stress
por: Hassan, Hozeifa M., et al.
Publicado: (2017)

Plasma Concentrations of sTREM-1 as Markers for Systemic Adverse Reactions in Subjects Treated With Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection
por: Wang, Tsai-Yu, et al.
Publicado: (2022)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid
por: de Oyarzabal, Eleane, et al.
Publicado: (2019)

Hepatoprotective activity of Ficus religiosa leaves against isoniazid+rifampicin and paracetamol induced hepatotoxicity
por: Parameswari, Sundaramoorthi Angala, et al.
Publicado: (2013)

Amelioration of hepatotoxicity by biocleavable aminothiol chimeras of isoniazid: Design, synthesis, kinetics and pharmacological evaluation
por: Bhilare, Neha Vithal, et al.
Publicado: (2018)

Alopecia caused by isoniazid
por: Dixit, Ramakant, et al.
Publicado: (2014)

An infrequent cause of persistent cough: endobronchial lipoma
por: Alves, Giordano Rafael Tronco, et al.
Publicado: (2013)

HSV-1 Ulcers as an Infrequent Cause of Hematochezia
por: Ahmed, Zarir, et al.
Publicado: (2020)

Infrequent and Potentially Missed Cause of Hypoxemia in an Infant
por: Elgabaly, Elham A, et al.
Publicado: (2019)

Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review
por: Shahid, Noor ul ain, et al.
Publicado: (2022)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

A study of the effect of Nigella sativa (Black seeds) in isoniazid (INH)-induced hepatotoxicity in rabbits
por: Hassan, Anwar S., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qei7bage73o8e4ma7foheoe51f